Table 1 Demographics and clinicopathological characteristics of EEC/AEH patients after achieving CR and attempting to conceive

Patients (n)

68

32

36

-

Age of initial treatment (years)

30.4 ± 3.9

31.0 ± 3.7

29.9 ± 4.1

0.272 ^a

Age of pregnancy permission (years)

31.9 ± 4.2

32.6 ± 3.8

31.2 ± 4.5

0.190 ^a

BMI ^c of initial treatment (kg/m²)

25.9 ± 4.2

26.9 ± 4.2

25.0 ± 3.9

0.051 ^a

BMI of pregnancy permission (kg/m2)

25.9 ± 3.8

27.2 ± 3.7

24.8 ± 3.6

0.007

Irregular menstrual cycle (%)

35 (51.5)

18 (56.2)

17 (47.2)

0.457 ^b

Infertility (%)

27 (39.7)

14 (43.8)

13 (36.1)

0.520^b

Nulliparity (%)

62 (91.2)

30 (93.8)

32 (88.9)

0.481 ^b

Diabetes mellitus type 2 (%)

11 (16.2)

3 (9.4)

8 (22.2)

0.151 ^b

Insulin resistance (%)

21 (30.9)

10 (31.3)

11 (30.6)

0.950 ^b

High blood pressure (%)

6 (8.8)

2 (6.2)

4 (11.1)

0.481 ^b

Thyroid diseases (%)

9 (13.2)

4 (12.5)

5 (13.9)

0.866 ^b

Myometrium invasion in MRI (%)

16 (33.3)

8 (34.8)

8 (32.0)

0.581 ^b

PCO on ultrasonography (%)

37 (54.4)

20 (62.5)

17 (47.2)

0.207 ^b

PCOS^d

27 (39.7)

13 (40.6)

14 (38.9)

0.884^b

CA125 (U/mL)

22.4 ± 22.6

22.7 ± 16.2

22.2 ± 27.2

0.926 ^a

Histological type

0.214 ^b

 AEH

39

16

23

 EEC G1

21

10

11

 EEC G2

8

6

2

Treatment protocol (%)

0.831 ^b

 MPA 250 mg, once daily

45 (67.2)

21 (65.6)

24 (68.6)

 MPA 500 mg, once daily

8 (11.9)

5 (15.6)

3 (8.6)

 MA 160-320 mg, once daily

9 (13.4)

4 (12.5)

5 (14.3)

 GnRH-a

5 (7.5)

2 (6.2)

3 (8.6)

Adjuvant metformin (%)

25 (36.8)

15 (46.9)

10 (27.8)

0.103 ^b

Maintenance therapy (%)

0.223 ^b

 None

11 (16.2)

6 (18.8)

5 (13.9)

 Progestin

45 (66.2)

18 (56.2)

27 (75.0)

 LNG-IUD

12 (17.6)

8 (25.0)

4 (11.1)

Conception method (%)

0.246 ^b

 Natural

19 (27.9)

12 (37.5)

7 (19.4)

 Ovulation induction ± IUI

9 (13.2)

4 (12.5)

5 (13.9)

 IVF-ET

40 (58.8)

16 (50.0)

24 (66.7)